Mark James Daniel
Known title: Chief Financial OfficerCIK: 0002092593
Associated companies
Transaction History
| ATOS | ▲ Buy | Grant | 63,000 | $0 | 3/26/2026 | View on chart |
| ATOS | ▲ Buy | Grant | 63,000 | $0 | 3/26/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target
Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.